Slide 1: Q4 2023 Supplemental Financial Information
February 27, 2024 Q4 2023 Supplemental Financial Information
Slide 2: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and twelve months ended December 30, 2023 and December 31, 2022, and for fiscal year ended December 31, 2021. Management believes that non-GAA
Slide 3: Q4 2023 Results
Q4 2023 Results Revenue by region and category Total by Category Q4 Revenue Year-Over-Year Change % of Total Revenue Business-to-business $18.1 million (33.6)% 23.8% domestic sales Business-to-business $21.5 million 4.0% 28.4% international sales Direct-to-consumer $19.8 million (21.6)% 26.1% domest
Slide 4: Full Year 2023 Results
Full Year 2023 Results Revenue by region and category Total by Category 2023 Revenue Year-Over-Year Change % of Total Revenue Business-to-business $66.2 million (23.1)% 21.0% domestic sales Business-to-business $89.4 million (11.6)% 28.3% international sales Direct-to-consumer $96.0 million (28.0)%
Slide 5: Operating Expense and Net Loss
Operating Expense and Net Loss (in thousands) Three months ended Twelve months ended December 31, December 31, 2023 2022 2023 2022 Operating expense Research and development $ 6,714 $ 5,934 $ 20,840 $ 21,943 Sales and marketing 25,653 28,606 107,091 120,767 General and administrative 24,773 1,259 75
Slide 6: Reconciliation of GAAP to Non-GAAP: Adjusted EBITDA
Reconciliation of GAAP to Non-GAAP Adjusted EBITDA (in thousands) Three months ended Twelve months ended December 31, December 31, Non-GAAP EBITDA and Adjusted EBITDA 2023 2022 2023 2022 Net loss (GAAP) $ (26,555) $ (56,610) $ (102,449) $ (83,772) Non-GAAP adjustments: Interest income, net (1,602) (
Slide 7: Reconciliation of GAAP to Non-GAAP: Adjusted Net Loss
Reconciliation of GAAP to Non-GAAP Adjusted Net Loss (in thousands) Three months ended December 31, Net Loss Diluted EPS Non-GAAP Adjusted Net Loss and Diluted EPS 2023 2022 2023 2022 Financial Results (GAAP) $ (26,555) $ (56,610) $ (1.14) $ (2.47) Non-GAAP adjustments: Amortization of intangibles 9
Slide 8: Stock-Based Compensation
Stock-Based Compensation (in thousands) Years ended December 31, 2023 2022 2021 Stock-based compensation expense by type of award: Restricted stock units and restricted stock awards $ 7,037 $ 11,748 $ 10,229 Employee stock purchase plan 390 535 714 Total stock-based compensation expense $ 7,427 $ 12
Slide 9: Improving lives through respiratory care
Improving lives through respiratory care